title: Reporter gene technology to assess activity of antimycobacterial agents in macrophages.
abstract: Reporter strains of Mycobacterium tuberculosis and Mycobacterium bovis BCG endogenously expressing firefly luciferase were used in bioluminescence assays to evaluate the activities of isoniazid and rifampin against mycobacteria sequestered in human macrophages. This methodology allowed the efficacy of antibiotics against intracellular mycobacteria to be assessed without the labor-intensive procedures and protracted incubation requirements associated with conventional CFU determinations.
authors.affiliation: Department of Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA. tarain@path.path.com
authors.forename: T M
authors.initials: TM
authors.lastname: Arain
authors.forename: A E
authors.initials: AE
authors.lastname: Resconi
authors.forename: D C
authors.initials: DC
authors.lastname: Singh
authors.forename: C K
authors.initials: CK
authors.lastname: Stover
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017930:Genes, Reporter / Q000187:drug effects*; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008156:Luciferases / Q000235:genetics; D008163:Luminescent Measurements; D008264:Macrophages / Q000382:microbiology*; D008826:Microbial Sensitivity Tests / Q000379:methods*; D009163:Mycobacterium bovis / Q000187:drug effects* / Q000235:genetics; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics; D011995:Recombination, Genetic; D012293:Rifampin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D008156:Luciferases; D007538:Isoniazid; D012293:Rifampin